ERAS News and Press, Erasca Inc. From 02/03/22

SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Gugg...

Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, dev...

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 40 ...

IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 Early collaboration with GCAR could support potential registrational path in GBM ERAS-801 is a highly CNS-penetrant EGFR inhi...

Erasca (NASDAQ:ERAS) is set to join the NASDAQ Biotech Index. The move is effective prior to market open on December 20, 2021. The oncology company reported its Q3 results last month. For further details see: Erasca to join NASDAQ Biotech Index

SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the company has been add...

Cumberland Pharmaceutical Inc. (NASDAQ: CPIX) has announced that the U.S. Food and Drug Administration has approved expanded labeling for Caldolor, a formulation of ibuprofen, to include use in pre-operative administration.  The FDA approved label includes information on ...

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Ever...

Erasca (NASDAQ:ERAS): Q3 GAAP EPS of -$0.46. Cash, cash equivalents, and investments of $486.6M Press Release For further details see: Erasca reports Q3 results

Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech’s “Fierce 15” most promising biotechnology companies of 2021 Donated $17.5 million of common shares t...